These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25039784)

  • 1. A glimpse of matrix metalloproteinases in diabetic nephropathy.
    Xu X; Xiao L; Xiao P; Yang S; Chen G; Liu F; Kanwar YS; Sun L
    Curr Med Chem; 2014; 21(28):3244-60. PubMed ID: 25039784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactive oxygen species and matrix remodeling in diabetic kidney.
    Ha H; Lee HB
    J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S246-9. PubMed ID: 12874440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases in kidney homeostasis and diseases.
    Tan RJ; Liu Y
    Am J Physiol Renal Physiol; 2012 Jun; 302(11):F1351-61. PubMed ID: 22492945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.
    Narula S; Tandon C; Tandon S
    Curr Med Chem; 2018; 25(15):1805-1816. PubMed ID: 29210632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats.
    Ni WJ; Ding HH; Zhou H; Qiu YY; Tang LQ
    Eur J Pharmacol; 2015 Oct; 764():448-456. PubMed ID: 26192633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.
    Dimas GG; Didangelos TP; Grekas DM
    Curr Vasc Pharmacol; 2017; 15(6):557-565. PubMed ID: 28155628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.
    Thrailkill KM; Clay Bunn R; Fowlkes JL
    Endocrine; 2009 Feb; 35(1):1-10. PubMed ID: 18972226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
    McLennan SV; Kelly DJ; Schache M; Waltham M; Dy V; Langham RG; Yue DK; Gilbert RE
    Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of matrix metalloproteinases in diabetes mellitus.
    Tsioufis C; Bafakis I; Kasiakogias A; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1159-65. PubMed ID: 22519446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney.
    Ha H; Lee HB
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S7-10. PubMed ID: 16174288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of matrix metalloproteinases in renal pathophysiologies.
    Catania JM; Chen G; Parrish AR
    Am J Physiol Renal Physiol; 2007 Mar; 292(3):F905-11. PubMed ID: 17190907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease.
    Zakiyanov O; Kalousová M; Zima T; Tesař V
    Adv Clin Chem; 2021; 105():141-212. PubMed ID: 34809827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy.
    McLennan SV; Martell SK; Yue DK
    Diabetes; 2002 Aug; 51(8):2612-8. PubMed ID: 12145178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy.
    Lee HB; Yu MR; Yang Y; Jiang Z; Ha H
    J Am Soc Nephrol; 2003 Aug; 14(8 Suppl 3):S241-5. PubMed ID: 12874439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of matrix metalloproteinases in development of diabetic nephropathy.
    Khasigov PZ; Ktzoeva SA; Gatagonova TM; Tareeva IE; Grachev SV; Berezov TT
    Biochemistry (Mosc); 2000 May; 65(5):519-24. PubMed ID: 10851028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
    Levin M; Udi Y; Solomonov I; Sagi I
    Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix Metalloproteinases in Diabetic Kidney Disease.
    Garcia-Fernandez N; Jacobs-Cachá C; Mora-Gutiérrez JM; Vergara A; Orbe J; Soler MJ
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32046355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
    Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
    Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy.
    McLennan SV; Death AK; Fisher EJ; Williams PF; Yue DK; Turtle JR
    Cell Mol Biol (Noisy-le-grand); 1999 Feb; 45(1):123-35. PubMed ID: 10099846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
    Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
    Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.